Changes in prostate cancer pattern according to prostate-specific antigen screening test

Korean Journal of Urology

Volumn 50, Issue 5, 2009, Pages 439-444

  Kwon, Jong Kyou ^a   In, Ho Chang ^a,b   Tae, Hyoung Kim ^a   Soon, Chul Myung ^a  

^a Chung Ang University   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

Author keywords

Mass screening; Prostate specific antigen; Prostatic neoplasms; Survival rate

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ARTICLE; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; PROSTATE CANCER; SURVIVAL RATE;

EID: 66649112864     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2009.50.5.439     Document Type: Article

References (19)

1. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999-2001: first result using the national cancer incidence database. Cancer Res Treat 2005;37:325-331
2. Korean National Statistical Office. The cause of death statistics, 1983-2003. Seoul: Korean National Statistical Office; 2005
3. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005;41:834-845
4. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate 2006;66:1285-1291
5. Jung KW, Yim SH, Kong HJ, Hwang SY, Won YJ, Lee JK, et al. Cancer survival in Korea 1993-2002: a population-based study. J Korean Med Sci 2007;22(Suppl):S5-10
6. Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol 1997;158:1427-1430
7. Okihara K, Kitamura K, Okada K, Mikami K, Ukimura O, MiM T. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. Int J Urol 2008;15:156-160
8. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29
9. Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence - data from the Utah Cancer Registry. Cancer 1996;77:1342-1348
10. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legier JM, Prorok PC, et al. Cancer surveillance series: interpreting trends in prostate cancer - part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91:1017-1024
11. Derweesh BH, Kupelian PA, Zippe C, Levin HS, Brainard J, Magi-Galluzzi C, et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 2004;22:300-306
12. American Cancer Society. Cancer facts and figures 2005. Atlanta: American Cancer Society; 2005
13. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: Does practice reflect the evidence? JAMA 2003;289:1414-1420
14. Okihara K, Nakanishi H, Nakamura T, Mizutani Y, Kawauchi A, Miki T. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing. Int J Urol 2005;12:662-667
15. Simone NL, Singh AK, Cowan JE, Soule BP, Carroll PR, Litwin MS. Pretreatment predictors of death from other causes in men with prostate cancer. J Urol 2008;180:2447-2451
16. Desireddi NV, Roehl KA, Loeb S, Yu X, Griffin CR, Kundu SK, et al. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology 2007;70:950-955
17. Park HK, Hong SK, Byun SS, Lee SE. Comparison of the rate of detecting prostate cancer and the pathologic characteristics of the patients with a serum PSA level in the range of 3.0 to 4.0 ng/ml and the patients with a serum PSA level in the range 4.1 to 10.0 ng/ml. Korean J Urol 2006;47:358-361
18. Sohn DW, Byun SS, Lee SE. Predictive factors and characteristics of the prostate cancer in patients with serum PSA levels equal or less than 4.0 ng/ml. Korean J Urol 2005;46:565-568
19. Lee SW, Byun SS, Lee SE. The diagnostic significance of abnormal findings on transrectal ultrasonography in patients with serum prostate-specific antigen levels equal or less than 4.0 ng/ml. Korean J Urol 2006;47:752-756